Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
91% of cloud leaders expect their cloud capabilities to be largely centralized within the next 2 years and 64% of cloud leaders have realized cybersecurity cost savings by migrating to cloud
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Medical Tourism will boost India’s economy
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
Subscribe To Our Newsletter & Stay Updated